Instructions for Authors

AJVR

Instructions for Authors

The mission of AJVR is to disseminate throughout the world the highest-impact, rigorously reviewed veterinary science research across the spectrum of species, using an online only, open access format for maximum accessibility. Manuscripts will be published as Gold open access and licensed using Creative Commons CC BY-NC. CC BY licensing is available upon request. An article processing fee of $1,250 will apply to accepted manuscripts.

The AJVR welcomes manuscripts of broad clinical relevance in the following categories: Original Research, Technical Tutorial Video, Systematic Review or Meta-Analysis, Narrative Review, Viewpoint, Case Report, and Did You Know. Letters to the Editor are also welcome. Currents in One Heath, and Spotlights are solicited by invitation only.

Authors are encouraged to determine the most appropriate category for their manuscript and then prepare their manuscript following the instructions provided below for that particular category. Questions can be sent to AVMAJournals@avma.org.

 

Before You Begin

Manuscript Categories

Manuscript Submission

Other Resources

 

Before You Begin

Why Publish With the AJVR?

Continuously published since 1940, the AJVR is one of the most well-regarded journals in the field of applied veterinary research. It is a widely circulated basic veterinary research journal and provides an important outlet for research likely to have an impact on veterinary clinical practice in the next few years.

We welcome submissions concerning all species—companion animals, equids, bovids and other farm animals, wildlife, and zoo animals. Your work will benefit from international visibility, downloads, and citations. In our new workflow, time from submission to publication is greatly reduced, while the redesigned website makes for an improved reading experience. Our robust social medial outreach platform will further support maximum dissemination of your paper. We urge you to consider the AJVR for your next article submission.

Back to top

Editorial Policies

Authorship

Individuals should be listed as authors only if they:

  • Made a substantial contribution to the conception or design of the study, acquisition of the data used in the study, or analysis and interpretation of that data, AND

  • Were involved in drafting or revising the manuscript critically for important intellectual content, AND

  • Will have the opportunity to approve the submitted and all subsequent versions, AND

  • Agree to be accountable for the validity of the data and results.

Individuals who contributed to the study but do not meet all 4 of these criteria should not be listed as authors but should be included in the Acknowledgments section. Requests to list a working group or study group in the byline will be handled on a case-by-case basis.

Back to top

Language
  • Authors are responsible for ensuring that their manuscripts are written clearly in English and formatted in accordance with these author instructions.

  • Manuscripts should be carefully reviewed prior to submission for format, clarity, spelling, and grammar.

  • A manuscript deemed by the editorial team to require extensive revisions prior to further consideration will be rejected with the option to resubmit after reformatting and/or editing has been performed.

  • The journal does not endorse any specific editing service, and provide these examples of suitable services authors that might consider include: CactusBioscience Writers, American Journal Experts, and the Nature Research Editing Service. Please note when working with a professional language editing service, authors should choose full medical editing with journal formatting, rather than simply proofreading, and that changes should comply with these instructions for authors.

Back to top

Acknowledgements, Disclosures, and Funding

Authors will be required to address these three statements during submission. This information does not need to be included in the manuscript document.

  • Acknowledgement/s: Identify individuals who made important contributions to the study but who do not meet the criteria for authorship. If none, include the statement “None reported.” 
  • Disclosure/s:
    • Include any conflicts of interest related to the manuscript. Include relevant financial interests (eg, ownership, employment, consultancies, honoraria, paid expert testimony, grants, patent-licensing arrangements, equity interests, and service as an officer or board member), activities, relationships, and affiliations (other than those listed on the title page of the manuscript). If none, include the statement “The authors have nothing to disclose.”
    • Include the use of any artificial intelligence (AI)–assisted technology such as ChatGPT or another Large Language Model in the writing of the manuscript or production of images. If none was used, include the statement “No AI-assisted technologies were used in the generation of this manuscript.” If an AI tool was used, the authors must be transparent in disclosing here, in the disclosures section, which AI tool was used and how the AI tool was used. AI tools cannot be listed as an author of a manuscript.
  • Funding: Include all funding, other financial support, and material support obtained directly or indirectly from any third party in connection with information included in the manuscript or with the writing or publishing of the manuscript. If none, include the statement “The authors have nothing to disclose.”

Back to top

  • All manuscripts will be published as Gold open access and licensed using Creative Commons CC BY-NC.
  • An article processing fee of $1,250 will apply to accepted manuscripts.
  • the corresponding author will be required to complete a Copyright License Agreement.
  • Permissions for use of Figures, Tables or other Content Owned by another party – If your manuscript contains previously published material (text, images, tables, photographs, drawings, etc.), you are responsible for providing proof of permission for re-use from the original copyright holder. At the time of submission of your manuscript to our journal, please include 1) permission for re-use of figures or tables and 2) a full citation for the previous publication. We cannot publish any previously published illustration or table without written permission from the original copyright holder.

Back to top

Commercial availability, compounding, and extralabel drug use
  • If a manuscript reports results of a study that involved evaluating a pharmaceutical, biologic, or other product that is not legally available in the USA for use in that species, then a clear disclaimer is needed in the materials and methods section describing where the drug is commercially available and that the drug is neither FDA approved nor commercially available in the US.
  • If compounded products/drugs were used in a study, an explanation in the Discussion section should include why the authors chose to use compounded products and what key factors should be considered by veterinarians interested in prescribing similarly prepared products.
  • Materials and Methods section should contain a complete description of the compounded products.
  • Extralabel drug use must comply with the provisions of the Animal Medicinal Drug Use Clarification Act.
  • Examples of the types of statements that would be appropriate for the Discussion section include the following:
    • Extralabel drug use was performed with owner consent and complied with provisions of AMDUCA and 21 CFR §530.
    • Compounded products were prepared from bulk substances because [provide reason]. Veterinarians should adhere to compounding regulations and be aware that pharmacokinetic properties may differ between compounded and FDA-approved products.
    • Compounded products were prepared from FDA-approved products because [provide reason]. Veterinarians should adhere to compounding regulations and be aware that pharmacokinetic properties may differ between compounded and FDA-approved products.

Back to top

Humane animal care and use

Back to top

Institutional oversight and owner consent
  • With the exception of reports of retrospective studies based solely on historical data, manuscripts describing studies that involved the use of animals, including studies that involved the use of privately owned animals (eg, animals owned by clients, staff members, students, or private entities), must include a statement that the study protocol was reviewed and approved by an appropriate oversight entity (eg, an animal care and use committee or institutional review board) or was performed in compliance with institutional or other (eg, governmental or international) guidelines for research on animals.

  • Prospective studies that involved privately owned animals must also include a statement indicating that informed owner consent was obtained.

  • Research involving human subjects, including surveys of human subjects, must include a statement that the research was performed under appropriate institutional review board oversight.

Back to top

NIH Public Access Policy

The AVMA journals are in compliance with the National Institutes of Health Public Access Policy and with the open access policies of other research funders.

Back to top

Patient confidentiality and the right to privacy
  • Authors have an obligation to protect the personal privacy of patients and clients and to maintain the confidentiality of patient-client information.

  • For any manuscript containing patient information (eg, patient descriptions, photographs, or pedigrees) that would allow specific animals or their owners to be identified, the authors must obtain a signed statement of informed consent to publish the information (in print and online) from the owners. Generally, such consent should include an opportunity for the owner to read the manuscript to be submitted for publication. If necessary, nonessential identifying data can be removed, unless clinically or epidemiologically important. However, identifying data may not be altered or falsified.

  • Cropping or altering photographs to remove nonessential identifying information is acceptable, so long as the photographs are not otherwise altered. Patient identifiers may not appear in photographs.

  • Authors must also obtain informed consent to publish from any identifiable person appearing in photographs. Importantly, these guidelines also apply to any materials (eg, text, photographs, or videos) submitted for posting as supplementary materials.

Back to top

Prior publication
  • Manuscripts are considered with the understanding that they have not been published previously and will not be submitted for publication elsewhere while under consideration by the AJVR.

  • Manuscripts submitted to the journal following or prior to presentation at a scientific meeting or publication of preliminary findings elsewhere, such as in abstract form, will be considered for publication. Publication of abstracts and posting of slides or videos of the scientific presentation in a print or online conference proceedings is acceptable.

  • Posting preprints of research manuscripts in progress or in submission on a public server is not considered prior publication and is also acceptable. Preprints are defined as research manuscripts that have not undergone formal peer review by a journal. Preprints may also be posted at any time during the review process.

  • Authors should disclose preprint posting, including DOI, URL link, and license details, at the time of manuscript submission or during the review process. Authors are requested to update any pre-publication versions with a link to the final published article.

  • Media coverage of presentations at scientific meetings will not jeopardize consideration, but direct release of results beyond what was included in the abstract through press releases or news media briefings may preclude consideration of the manuscript by this journal.

Back to top

Journal Style

The AVMA journals generally follow the guidance provided in the most recent edition of the AMA Manual of Style. More specific instructions are provided in each of the linked items listed under Manuscript Categories and Other Resources at the top of this page.

Back to top

Reporting Guidelines

Authors of Original Research or Systematic Reviews/Meta-Analyses are strongly encouraged to make use of the following guidelines when preparing manuscripts:

  • CONSORT (Consolidated Standards of Reporting Trials)—for clinical trials

  • REFLECT (Reporting Guidelines for Randomized Controlled Trials for Livestock and Food Safety)—for clinical trials in livestock and food safety

  • PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-analyses)—for systematic reviews and meta-analyses

  • STARD (Standards for the Reporting of Diagnostic Accuracy Studies)—for diagnostic test evaluation

  • STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)—for cross-sectional, case-control, and cohort studies

  • ARRIVE (Animal Research: Reporting of In Vivo Experiments)—for all studies involving laboratory animals

  • SRQR (Standards for Reporting Qualitative Research)—for all studies involving qualitative research

  • SAMPL (Statistical Analyses and Methods in the Published Literature)—for all studies

  • CLAIM (Checklist for Artificial Intelligence in Medical Imaging)—for studies involving AI in diagnostic imaging

Information on reporting guidelines is available through the EQUATOR (Enhancing the Quality and Transparency of Health Research) Network

Back to top

Manuscript Categories

There are five categories of manuscripts, with varying maximum word counts and other criteria. Links to specific instructions for each are given below:

Back to top

Manuscript Submission

General Information

To submit manuscripts, please visit https://mc.manuscriptcentral.com/ajvr.

Note, an article processing fee of $1,250 will apply to accepted manuscripts.

For author and pre-submission inquiries, please contact AVMAJournals@avma.org. For details on AVMA news, conferences or other AVMA information, please visit avma.org.

Back to top

Submission Checklist—Ensure the Following:

  • If accepted, the authors agree to pay an open access article processing charge of $1,250.
  • One author has been designated as the corresponding author with contact details:
    • Email address.
    • Full postal address.
  • The manuscript has been checked for spelling and grammar.
  • Abbreviations and preferred pharmacologic and pharmacokinetics terminology, pulmonary and respiratory terminology, and radiographic projection naming are used in accordance with journal guidelines.
  • All references mentioned in the reference list are cited in the text.
  • Footnotes are not used (review the instructions on citing special materials for information on citing materials previously included as footnotes).
  • Permission has been obtained for use of copyrighted material from other sources.
  • Journal policies detailed in this guide have been reviewed.
  • All necessary files have been uploaded:
    • Manuscript.
    • Keywords.
    • Figures (include relevant captions), with the same figure names (eg, Figure 1) as used in the manuscript.
    • Supplementary files (where applicable).
  • We strongly encourage a cover letter containing the following information:
    • Why is this study important? (2 or 3 sentences)
    • What did you find? (2or 3 sentences)
    • Why is this study of wide interest? (2 or 3 sentences)
    • Is the manuscript for resident credentialling or promotion?
    • Suggested 6-10 reviewers with their names and email addresses.

Back to top

Publication Platforms and Associated Fees

  • All AJVR manuscripts are published open access in the AJVR. Open access articles will be licensed under the Creative Commons CC BY-NC license.

  • All accepted manuscripts will be subject to open access article processing charges (APC). An APC of $1,250 will be invoiced upon acceptance of a manuscript.

Back to top